Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 90
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 42
Neuropathogenesis-on-chips for neurodegenerative diseases
Sarnai Amartumur, Huong Mai Nguyen, Thuy Huynh, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 21
Alzheimer's disease pathophysiology in the Retina
Bhakta Prasad Gaire, Yosef Koronyo, Dieu‐Trang Fuchs, et al.
Progress in Retinal and Eye Research (2024) Vol. 101, pp. 101273-101273
Open Access | Times Cited: 20
Disentangling tau: One protein, many therapeutic approaches
Courtney Lane‐Donovan, Adam L. Boxer
Neurotherapeutics (2024) Vol. 21, Iss. 2, pp. e00321-e00321
Open Access | Times Cited: 16
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
The advent of Alzheimer treatments will change the trajectory of human aging
Dennis J. Selkoe
Nature Aging (2024) Vol. 4, Iss. 4, pp. 453-463
Closed Access | Times Cited: 12
Genomic stress and impaired DNA repair in Alzheimer disease
Jolien Neven, Luidy Kazuo Issayama, Ilse Dewachter, et al.
DNA repair (2024) Vol. 139, pp. 103678-103678
Closed Access | Times Cited: 9
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Zhongqing Sun, Xin Zhang, Kwok‐Fai So, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 833-833
Open Access | Times Cited: 5
Incidence and Prevalence of Early-Onset Dementia in Finland
Johanna Krüger, Mikko Aaltonen, Kalle Aho, et al.
Neurology (2024) Vol. 103, Iss. 4
Open Access | Times Cited: 5
Approved drugs and natural products at clinical stages for treating Alzheimer’s disease
Yajing Ma, Sufang Liu, Qingfeng Zhou, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 8, pp. 699-710
Closed Access | Times Cited: 5
Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
Caitlin M. Terao, Madeline Wood Alexander, R. Philip Chalmers, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2025) Vol. 17, Iss. 1
Open Access
HEBE: A novel chimeric chronokine for ameliorating memory deficits in Alzheimer’s disease
Jon Esandi, Pedro Renault, Maria Dolores Capilla-López, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117815-117815
Closed Access
Synaptic vulnerability to amyloid-β and tau pathologies differentially disrupts emotional and memory neural circuits
Maria Dolores Capilla-López, Ángel Deprada-Fernandez, Yuniesky Andrade‐Talavera, et al.
Molecular Psychiatry (2025)
Open Access
The Role of Brain-Derived Neurotrophic Factor as an Essential Mediator in Neuronal Functions and the Therapeutic Potential of Its Mimetics for Neuroprotection in Neurologic and Psychiatric Disorders
Tadahiro Numakawa, Ryutaro Kajihara
Molecules (2025) Vol. 30, Iss. 4, pp. 848-848
Open Access
Eligibility for donanemab trial in a population-based study of cognitive aging
Katherine E. Jones, Jeremiah A. Aakre, Anna Castillo, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100088-100088
Open Access
Quantitative simulation of near-infrared light treatment for Alzheimer’s disease using patient-individualized optical-parametric phantoms
Sihan Dong, Rui Zhang, Jun Xue, et al.
Neurophotonics (2025) Vol. 12, Iss. 01
Open Access
A Federated Data Analysis Approach for the Evaluation of Surrogate Endpoints
Dries De Witte, Ariel Alonso, Diane Stephenson, et al.
Pharmaceutical Statistics (2025) Vol. 24, Iss. 2
Closed Access
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Leonardo Iaccarino, Samantha Burnham, Ilke Tunali, et al.
NeuroImage Clinical (2025) Vol. 46, pp. 103765-103765
Open Access
Fight Aβ Aggregation with Molecular Aggregates
Cheng Wang, Dingxin Zhang, Ming Hu, et al.
Macromolecular Chemistry and Physics (2025)
Closed Access
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities
Giovanni B. Frisoni, Federica Ribaldi, Gilles Allali, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100098-100098
Open Access
Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions
Jeffrey L. Cummings
Neurotherapeutics (2025), pp. e00570-e00570
Open Access
The impact of arteriolosclerosis on cognitive impairment in decedents without severe dementia from the National Alzheimer's Coordinating Center
Cellas A. Hayes, Christina B. Young, Carla Abdelnour, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access
Potential of molecular chaperones for treating Alzheimer’s disease
Gefei Chen, Jan Johansson
Neural Regeneration Research (2024) Vol. 19, Iss. 11, pp. 2343-2344
Open Access | Times Cited: 4
Cognitive modeling of the Mnemonic Similarity Task as a digital biomarker for Alzheimer’s Disease
Casey R. Vanderlip, Michael Lee, Craig E.L. Stark
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top